top of page

RESUME

Kitap_Reklam__edited.avif
"We must raise generations who wait, are patient, are motivated
that is, who stop, think, and then act"

Dr. Tanju Sürmeli

Psychiatrist Dr. Tanju Sürmeli,

He graduated from Dokuz Eylül University Faculty of Medicine in 1984, receiving the title of "Medical Doctor". Afterwards, he went to America for his psychiatry residency, where he completed his Psychiatry, Internal Medicine, and Neurology residency training with ECFMG certification at the Institute of Living/U.Conn., Yale, University of Texas, and San Antonio University Hospitals, and completed an EEG and Psychopharmacology Research Fellowship at New York Medical College. He successfully completed the Harvard Medical School Global Clinical Scholar Research Training Program. He continues his work with Harvard. He submitted a project to Harvard Medical School, in collaboration with Johns Hopkins Medical School, to conduct a placebo-controlled neurofeedback study on Alzheimer's disease. His application for associate professorship was sent to the jury appointed by the Council of Higher Education (YÖK) for review of his work.

He received training in Family Therapy at the Ackerman Institute for Family Therapy (Cornell affiliated) and in Hypnosis at the Milton Ericson Hypnosis Institute in New York. At Columbia-NYSPI and the Manic Depression Foundation, he participated as a principal investigator in various antidepressant drug studies on bipolar disorder and depression with Prof. Dr. Ronald Fieve.

On August 22, 2000, he passed the equivalency exam at Ege University Psychiatry Department, thus gaining the right to become a psychiatrist in Turkey. Shortly after returning to Turkey (in 2001), he founded the Healthy Living Clinic. He pioneered the use of QEEG, neurometric examination, Loreta, and neurobiofeedback digital systems in Turkey, which positively contribute to the brain's maturation and healing power, and provided individual training to over 26,000 families on correct parenting styles. He is currently a consultant supporting an animated film project developed by expert psychologist Ayben Ertem, which aims to reduce parenting mistakes and contribute to the development of healthier brains.

In 2007, he became the founder and president of the Association for the Use of Biofeedback, Neurofeedback, QEEG and ERP in Psychiatry. He contributed to the inclusion of Biofeedback in the list of treatment methods that can be applied in private practices by the Turkish Ministry of Health. He is fighting for the establishment of Biofeedback as a drug-free treatment method in Turkey and for its coverage by the Social Security Institution (SUT). He is the only BCIAC-EEG certified and academic member in Turkey of the American International Biofeedback Certification Association (BCIA).

In 2014, he was elected as an International Academic Member to the International Electrophysiology QEEG Board of Directors, headquartered in Chicago, for a four-year term, among 12 academic members, with the aim of providing exams and training to prepare psychiatrists, neurologists, and PhD scientists worldwide for EEG and QEEG certification. This board is supported by the Clinical EEG and Neuroscience Society, formed in 1998 by the merger of the American Psychiatric Electrophysiology Association (APEA) and the American Medical EEG Association (AMEEGA).

In 2015, he was elected as an international member to the nine-member Board of Directors of the International Society for Neurofeedback and Research (ISNR), one of two important organizations in America that determine the criteria for whether the clinical effectiveness of biofeedback/neurofeedback therapy has been scientifically proven through research, and that certifies biofeedback/neurofeedback therapy by providing training to psychiatrists, neurologists, physiotherapists, pediatricians, dentists, and doctoral psychologists.

He is also a founder and Board Member of the European Society of Applied Neuroscience. He is a member of international associations (AMA, APA, AAPB, ISNR, SAN, BFE, ECNS) and holds faculty positions as an instructor in workshops. He serves as a reviewer for scientific articles in the journals Clinical EEG and Neuroscience, Psychiatry Research, and Journal of Child Psychology and Psychiatry.

The Swiss Academy of Sciences Foundation requested him to be an expert reviewer for "Neurofeedback in Schizophrenia" in 2015, for "Neurofeedback in Bipolar Disorder and Borderline Personality Disorder" in 2017, and for "Neurofeedback in residual symptoms of Bipolar Disorder" in 2018. Scientists at prestigious universities such as Harvard, Johns Hopkins, and U. Penn seek his consultation for QEEG and Neurofeedback studies. Since 2014, Times Higher Education has asked him to serve as a judge in THE World University Rankings and THE World Reputation Rankings due to his outstanding track record as a senior academic.

He served as a member of the Scientific Advisory Board for Neurotech's Mente autism neurofeedback device in 2018-2019.

Professor Dr. John Gruzelier from Imperial College Medical School in England requested that Dr. Sürmeli be involved in the Turkish leg of the European Union's COST B27 Electric Neuronal Oscillations and Cognition project. Between 2005 and 2010, Dr. Tanju Sürmeli served on the executive committee of the COST B-27 Action (ENOC - Electric Neuronal Oscillations), a 5-year project with a budget of 24 million Euros, in which TUBITAK also participated. He was the Turkish representative within the COST (European Cooperation in the field of Scientific and Technical Research) B-27 action (ENOC - Electric Neuronal Oscillations), an organization of the European Union. He played a role in the examination of the therapeutic effects of EEG biofeedback in various diseases by a large group of researchers conducting clinical studies, in the transfer of clinical experiences, in the scientific evaluation of existing neurofeedback protocols, and in communicating to the population in America and many European countries, where neurofeedback is widely used for therapeutic purposes, which protocols should be applied in which diseases and how.

Studies demonstrating the clinical effectiveness of neurofeedback therapy in Down Syndrome, Intellectual Disability, Antisocial Personality Disorder, Obsessive-Compulsive Disorder, Schizophrenia, and Alzheimer's Disease have been published in prestigious international journals.

AWARDS

  • The Neurofeedback and Applied Neuroscience Foundation (FNAN) in the United States awarded Dr. Tanju Sürmeli and his team the "QEEG-Guided Neurofeedback Treatment for Schizophrenia: A Clinical Case Series" award for their publication in the April 2012 issue of "Clinical EEG and Neuroscience," recognizing it as the publication that most advanced the field of Neurofeedback during the previous year.

  • [EEG and Psychopharmacology Research Fellowship, New York Medical College]

BOOKS

  • Wake up call. The Healing Power of the Brain: the importance of nonpharmacologic approach: Neurofeedback and QEEG in Psychiatry. Nobel Medicine 2016. 380 Pages Turkish (in review). To be published in English.

  • ​

  • Tanju Surmeli. The Healing Power of the Brain: the importance of Neurofeedback and QEEG in Psychiatry. 2010, page, Publisher Nobel Medicine.

BOOK CHAPTER/REVIEW/PREFACE

  • Clinical Neurotherapy: Application of Techniques for Treatment, Edited by David S. Cantor and James R. Evans “Treating Thought Disorders” chapter 9 by Tanju Surmeli Elsevier (2014).Page 213-251.​

​

  • 4th Edition of Evidence-based Practice in Biofeedback & Neurofeedback Gabriel Tan, Fredric Shaffer, Randall Lyle, Irene Teo, Randall Lyle: Evidence supporting neurobiofeedback in Schizophrenia. (2021) by Association for Applied Psychophysiology and Biofeedback. (accepted)

​​

  • 2nd Edition of Neurofeedback and Neuromodulation Techniques and Applications, Edited by Robert Cohen and James R. Evans, Chapter 11: Evidence supporting neurofeedback for adult psychiatric disorders by Surmeli, T. Elsevier (2021) Elsevier (in review)

​​

  • Neurofeedback The  First  Fifty  Years.  Edited   by  James   R.  Evans  Mary  Blair   Dellingerharold  L.Russell. Bölüm 54. My career in QEEG and neurofeedback  by Tanju Surmeli (2020) Elsevier. 427. ISBN: 978-0-12-81765

​​

  • Foreword: Antidepresan Efsanesinin Sonu by Prof. Irving Kirsch, 2012 Publisher Kural disi. (Turkish version of The Emperor's New Drugs: Exploding the Antidepressant Myth. (2010). Pages: 228. ISBN: 978-975-275-194-1

SCIENTIFIC PUBLICATIONS

  • Ros T, Enriquez-Geppert S, Zotev V, Young KD, Wood G, Whitfield-Gabrieli S, Wan F, Vuilleumier P, Vialatte F, Van De Ville D, Todder D, Surmeli T, Sulzer JS, Strehl U, Sterman MB, Steiner NJ, Sorger B, Soekadar SR, Sitaram R, Sherlin LH, Schönenberg M, Scharnowski F, Schabus M, Rubia K, Rosa A, Reiner M, Pineda JA, Paret C, Ossadtchi A, Nicholson AA, Nan W, Minguez J, Micoulaud-Franchi JA, Mehler DMA, Lührs M, Lubar J, Lotte F, Linden DEJ, Lewis-Peacock JA, Lebedev MA, Lanius RA, Kübler A, Kranczioch C, Koush Y, Konicar L, Kohl SH, Kober SE, Klados MA, Jeunet C, Janssen TWP, Huster RJ, Hoedlmoser K, Hirshberg LM, Heunis S, Hendler T, Hampson M, Guggisberg AG, Guggenberger R, Gruzelier JH, Göbel RW, Gninenko N, Gharabaghi A, Frewen P, Fovet T, Fernández T, Escolano C, Ehlis AC, Drechsler R, Christopher deCharms R, Debener S, De Ridder D, Davelaar EJ, Congedo M, Cavazza M, Breteler MHM, Brandeis D, Bodurka J, Birbaumer N, Bazanova OM, Barth B, Bamidis PD, Auer T, Arns M, Thibault RT. Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist). Brain. 2020 Jun 1;143(6):1674-1685. doi: 10.1093/brain/awaa009. PMID: 32176800; PMCID: PMC7296848.​​

  •  Duric NS,  Assmus J, Børresen H, Alisa Duric Golos  AD, Socanski D, Duric A, Surmeli T. (2020). The quantitative EEG in attention deficit hyperactivity disorder and normal controls: behavioral and age correlates. Clinical EEG and Neuroscience (in review)​​

  • Surmeli T, Eralp E, Mustafazade I, Kos H, Özer GE, Surmeli OH. (2016). Quantitative EEG Neurometric Analysis-Guided Neurofeedback Treatment in Dementia: 20 Cases. How Neurometric Analysis Is Important for the Treatment of Dementia and as a Biomarker? Clin EEG Neurosci., Vol 47(2)118-133.​​

  • Keeser D.1,2, Karch S.1, Davis J.R.3, Surmeli T.4, Engelbregt H.1,5,  Minton B.5, Berd A.5, Thatcher R.W.6,  Pogarell O1.(2013). Changes of resting-state EEG and functional connectivity in the sensor and source space of patients with Major depression. Klinische Neurophysiologie 03/2013; 44(01). DOI:10.1055/s-0033-1337283.

  • ​Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich, Germany

  • Institute for Clinical Radiology, Ludwig-Maximilian University Munich, Germany

  • Department of Psychiatry and Behavioral Neurosciences, Michael G. DeGroote School of Medicine, McMaster University, Ontario, Canada

  • Living Mental Health Center for Research and Education, Istanbul, Turkey

  • Hersencentrum, Amsterdam, The Netherlands

  • NeuroImaging Laboratory, Applied Neuroscience Research Institute, St. Petersburg, Florida​​

  • Prichep, L.1, Surmeli, T.2, Thatcher, R. W.3, Koberda, L.4, Ottes, G. and Berdyugina, A. (2016). QEEG and Traumatic Brain Injury: Evidence based medicine analyses. J Clin Psychiatry (In Review)

  • ​Professor of Psychiatry. Department of Psychiatry , NYU, NY .US.

  • Living Mental Health Center for Research and Education, Istanbul, Turkey

  • NeuroImaging Laboratory, Applied Neuroscience Research Institute, St. Petersburg, Florida

  • Florida State University College of Medicine. Professor of Neurology and Director of Tallahassee NeuroBalance Center​​

  • Surmeli, T. (2015). Bilinçaltının Gücünü Keşfedin. Bilinçaltını Daha İyi Kullanan Bir Lider Olabilirsiniz. Nöroliderlik ve Peak Performans. Harvard Business Review (in review).​

  • Surmeli, T. Ertem, A., Eralp,E. Kos, I.H.(2016).Posttraumatic Stress Disorder, Posttraumatic Stress Disorder-Like Symptoms Due to Mild Traumatic Brain Injury and Comorbidity. How QEEG is helpful in diagnosis and personalized treatment? Review. Neuroscience & Biobehavioral Reviews (in review).​

  • Cannon RL, Pigott HE, Surmeli T, Simkin DR, Thatcher RW, Van den Bergh W, Gluck G, Lubar JF, Davis R, Foster DS, Douglas J, Malcolm AT, Bars D, Little K, Center W, Berman M, Russell H, Hammer B, Koberda JL.The problem of patient heterogeneity and lack of proper training in a study of EEG neurofeedback in children. J Clin Psychiatry. 2014 Mar;75(3):289-90. doi: 10.4088/JCP.13lr08850.​

  • Surmeli, T. Ertem, A., Eralp,E. Kos, I.H. (2016). Incorrect Diagnosis and Ineffective Treatment of Attention Deficit Hyperactivity (ADHD) May Decrease Children’s IQ, The Efficacy of QEEG and Neurofeedback in the Assessment and Treatment of ADHD/Learning Disability (LD) and Post Neurofeedback IQ Increase: A Clinical Case Series. Clin EEG Neurosci (in review).​

  • Surmeli, T. Ertem, A., Eralp,E. Kos, I.H. (2015). Quantitative EEG Neurometric Analysis–Guided Neurofeedback Treatment in Post Concussive Syndrome (PCS): 40 Cases. How Neurometric Analysis Is Important for the Treatment of PCS and as a Biomarker? Clinical EEG Neuroscience (in review).​

  • Surmeli, T. Ertem, A., Eralp,E (2015).The Efficacy of QEEG and Neurofeedback in the Diagnosis and Treatment of Post Concussion Sydrome with paronoia: 20 patients case study. Journal of Head Trauma Rehabilitation (in review).​

  • Surmeli, T., Eralp, E., Ertem, A., Mustafazade I, Kos, I. H., Ozer G.E.(2015). The Effects of QEEG Guided Neurofeedback (NF) Treatment on patients with Intellectual Disability: 67 Case. Clin EEG Neurosci (in review).​

  • Surmeli, T., Ertem, E., Eralp, E., & Kos, I. H. (2012). Schizophrenia and the efficacy of qEEG-guided treatment: A clinical case series. EEG & Clinical Neuroscience. Vol 43. Number 2, 133-144​

  • Surmeli, T., & Ertem, A., Eralp,E. (2011) Obsessive Compulsive Disorder and the Efficacy of qEEG-Guided Neurofeedback Treatment: A Case Series. Clinical EEG and Neuroscience July 2011, Vol 42,Number 3, 195-201.​

  • Surmeli, T., & Ertem, A. (2010). Post WISC-R and TOVA improvement with QEEG guided neurofeedback training in Mentally Retarded: 23 Cases. Clinical EEG and Neuroscience. Jan, 40 (1), 32-41.​

  • Surmeli, T., & Ertem, A. (2009). QEEG guided neurofeedback therapy in personality disorders: 13 case studies. Clinical EEG and Neuroscience, 40 (1), 6-10.​

  • Surmeli, T. (2009). QEEG-Neurometric analysis Guided Neurofeedback treatment in Medicated Schizophrenia patients. Case Study: 52 patients: How Neurometric Analysis is Important at the treatment of Schizophrenia as well as Diagnosis? Clinical EEG and Neuroscience, Volume 40, Number 1, 206-220, July.​

  • Surmeli, T. (2009). QEEG-Neurometric analysis Guided Neurofeedback treatment in Medicated Schizophrenia patients. Case Study: 53 patients: How Neurometric Analysis is Important at the treatment of Schizophrenia as well as Diagnosis? Neuropsychobiology Feb 27; 58:244-245.​

  • Surmeli T., & Ertem, A. (2007). EEG Neurofeedback Treatment of Patients with Down Syndrome, Journal of Neurotherapy,Volum 11,Page 63-68,Number 1.​

  • Surmeli, T, Ertem, A. (2004). Efficacy of Neurofeedback in language and speech problems due to Mental Retardation,II. National Language and Speech Disability Research Book, page 214-227.​

  • Surmeli, T., Ertem,A. (2003). Neurofeedback and Special Education, 13. National Special Education Research Book, page 173-176,2003.

DOMESTIC WORKSHOPS, CONFERENCES AND PRESENTATIONS

  • Istanbul Arel University Electronics, Computer, Biomedical Engineering Scientific Meeting – EBBT2016”, “Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method. Its Role in Diagnosis, Treatment and Performance Enhancement” April 27, 2016.

  • Yeditepe University Faculty of Medicine Dean's Office, “Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method. Its Role in Diagnosis, Treatment and Performance Enhancement” April 20, 2016.

  • Acıbadem University Faculty of Medicine Dean's Office, “Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method. “The Role of Biomarker QEEG and Neurobiofeedback in Diagnosis, Treatment, and Performance Enhancement” March 31, 2016.

  • Dokuz Eylül University Faculty of Medicine Dean's Office, “Biomarker QEEG and Neurobiofeedback: The Role of Biomarker QEEG and Neurobiofeedback in Diagnosis, Treatment, and Performance Enhancement” February 26, 2015.

  • Montana State University and Istanbul Technical University Bioengineering “Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method. The Role of Biomarker QEEG and Neurobiofeedback in Diagnosis, Treatment, and Performance Enhancement” May 3-4, 2014.

  • Yıldız Technical University Bioengineering. “Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method. "The Role of Diagnosis, Treatment and Performance Enhancement" May 29, 2014.

  • Cerrahpaşa Faculty of Medicine, Istanbul University Psychology Days, "Biomarker QEEG and a Non-Pharmacological Approach: Neurobiofeedback Method." Its role in Diagnosis, Treatment and Performance enhancement“ 5.4.2012.​

  • Koç University, Neurofeedback and Peak Performance; Education Seminars.​

  • Yıldız Technical University- Peak Performance.​

  • Marmara University Sports College- Peak Performance.​

  • Istanbul University Sports College Peak Performance and Biofeedback.​

  • The Improvement of WISC-R and TOVA Scores Using QEEG Guided Neurofeedback Training in Learning Disabilities due to Delayed Mental Development: 23 patient Case Study. Pediatric Rehabilitation Congress, Istanbul, 2009.​

  • The Importance of FDA Approved QEEG Databases in the Diagnosis and Treatment of Psychiatric Disorders. 12th National Psychology Congress, Middle East Technical University, Ankara 2002.​

  • Neurofeedback and Special Education. 13th National Special Education Congress, Anadolu University, Eskisehir, 2003.​

  • The Effect of Neurofeedback in Speech and Language Problems in the Mentally Retarded: 24 Patient Case Study. 2nd National Language and Speech Pathology Congress, Anadolu University, Eskişehir, 2004.

DOMESTIC TRAINING SEMINARS

Eduworks 13th Leadership Submit, 2016, Istanbul.

​​

Eduworks 11th Leadership Submit, 2014, Istanbul.

​​

  • Edu Plus 6th Personal Development Summit, 2011, Istanbul.​

  • Peak Performance, The Brain and Education. Private Schools Congress Antalya, 2011.​

  • Edu Plus 5th Personal Development Summit, 2010, Istanbul.​

  • Şükrü Balcı Police Academy- Peak Performans.​

  • Doğan Hospital / QEEG-Neurofeedback Training and its Benefits, Peak Performans.

INTERNATIONAL CONFERENCES AND PRESENTATIONS

  • Neurofeedback can treat Schizophrenia: Delusion or reality? INA 2015, October 15. Jerusalem, Israel.​

  • The Effects of QEEG Guided Neurofeedback Treatment on patients with Intellectual Disability: A Clinical Case Series. r-FMRI and Neurofeedback Meeting, Şubat 11-12, 2015. University of Florida. Gainsville, Florida (Poster).​

  • QEEG-Neurometric Analysis Guided Neurofeedback (NF) Treatment In Dementia: 20 Cases. How Neurometrıc Analysis Is Important For The Treatment Of Dementia As Well As Diagnosis?”BFE 17th annual meeting, Istituto Universitario Salesiano Venezia (IUSVE) Venice, Italy, February 11-15, 2014; AAPB 45th Annual Scientific Meeting Savannah, Georgia March 19-22, 2014.​

  • QEEG-Neurometric Analysis Guided Neurofeedback (NF) Treatment In Dementia: 20 Cases. How Neurometric Analysis Is Important For The Treatment of  Dementia as well as Diagnosis? Basic and Clinical Multimodal Imaging (BaCI), a Joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source Imaging (ISFSI), the International Society for Bioelectromagnetism (ISBEM), the International Society for Brain Electromagnetic Topography (ISBET), and the EEG and Clinical Neuroscience Society (ECNS),  Geneva, Sept. 4-8, 2013.

  • QEEG-Neurometric Analysis Guided Neurofeedback (NF) Treatment In Dementia: 23 Cases. How Neurometrıc Analysis Is Important For The Treatment Of Dementia As Well As Diagnosis?”1st Istanbul-Euroasia Regional Congress of Biological Psychiatry, May 27-31 2012.​

  • PTSD, PTSD-like Symptoms due to Mild Traumatic Brain Injury and Comorbidity:How QEEG is Helpful in Diagnosis and Personalized Treatment? Invisible wounds, New tools to enhance PTSD diagnosis and Treatment, 2012 NATO Advanced Study Institute,June 18 - 28, 2012, Ankara, Turkey.​

  • Incorrect Diagnosis and Ineffective Treatment of Attention Deficit Hyperactivity (ADHD) May Decrease Children’s IQ, The Efficacy of QEEG and Neurofeedback in the Assessment and Treatment of ADHD/Learning Disability (LD) and Post Neurofeedback IQ Increase: A Clinical Case Series. Excellence in Child Mental Health Schools Meeting in Istanbul, 30 Nov-3 Dec, 2011 and Poster NR4-58 American Psychiatric Association Annual Meeting, Philadelphia PA, May 6, 2012.​

  • QEEG-Neurometic Analysis Guided Neurofeedback Treatment in Schizoprenia: 51 patient case study. 6th International Conference on Psychiatry Dhaka,Bengaldesh, 16-18 October 2011.​

  • The Efficacy of QEEG and Neurofeedback in the Diagnosis and Treatment of Post Concussion Sydrome: 40 patients case study. The Annual Meeting of the International Society of NeuroImaging in Psychiatry with the International Society for Brain Electromagnetic Topography (ISBET) and the EEG and Clinical Neuroscience Society  in Heidelberg, Germany, September 7 - 10, 2011.​

  • QEEG-Neurometic Analysis Guided Neurofeedback Treatment in Schizoprenia: 51 patient case study.  SAN annual meeting Athens, 2011.​

  • QEEG-Neurometic Analysis Guided Neurofeedback Treatment in Schizoprenia: 51 patient case study.  BFE annual meeting Germany, 2010.​

  • The Importance of QEEG-Neurometic Analysis Guided Neurofeedback Treatment in the Diagnosis and Treatment of Dementia: 9 patient case study.  SAN annual meeting Prag, 2009.​

  • The Efficacy of QEEG and Neurofeedback in the Diagnosis and Treatment of Post Concussion Sydrome: 24 patient case study. AAPB Yearly Meeting, Albuquerque, New Mexico, 2009.​

  • QEEG Guided Neurofeedback Treatment in Personality Disorders: 13 Patient Case Study.  ECNS/ISNP (EEG &Clinical Neuroscience Society) Meeting, Montreal, September 2007.​

  • The Role of QEEG Guided Neurofeedback in the Diagnosis and Treatment of Post Concussion Sydrome:24 Patient Case Study. ISNR Meeting, USA, 2008.​

  • QEEG Guided Neurotherapy in Dementia: 3 Patient Case Study.  SAN, Nijmegen, NL, 2007.​

  • The Improvement of WISC-R and TOVA Scores after QEEG Guided Neurofeedback in Learning Disabilities.  BFE 11th Annal Meeting, Berlin 2007.​

  • The Improvement of WISC-R and TOVA Scores after QEEG Guided Neurofeedback in Mental Retardation.  SAN 2nd h Annal Meeting, Seville 2008.​

  • “Characterizing Subtypes” Symposium Chairman. SAN’s Science and Technology Meeting (COST) with the partnership of B27 EU, Wales, 2006.

  • QEEG-Neurometic Analysis Guided Neurofeedback Treatment in Schizoprenia. SAN’s Science and Technology Meeting (COST) with the partnership of B27 EU, Wales, 2006.​

  • QEEG-Neurometic Analysis Guided Neurofeedback Treatment in Schizoprenii. 52 Patient Case study. 4th ECNS/ISNP(EEG & CLINICAL NEUROSCIENCE SOCIETY) Meeting Frankfurt September 2008, and IPEG (International Pharmaco EEG Society)(http://www.forenap.com/ipeg/home.php) Meeting Roufach, France, 2008; AAPB Meeting, USA, 2009.​

  • The Importance of Neurometic Analysis in both Diagnosis and Treatment. SAN’s Science and Technology Meeting (COST) with the partnership of B27 EU, Wales, 2006.​

  • The Effect of Neurofeedback in Speech and Language Problems in the Mentally Retarded: 24 Patient Case Study. SAN’s Science and Technology Meeting (COST) with the partnership of B27 EU, Wales, 2006.​

  • QEEG Guided Neurofeedback Treatment in Personality Disorders: 13 Patient Case Study.  BFE Vienna 2006.​

  • EEG Biofeedback Training of the Right and Left Hemispheres in Autistic Spectrum Disorders: 22 patient Case Study.  SAN Meeting Istanbul.​

  • The Effects of Decreasing Delta Activity Using Neurofeedback in 16 Mentally Retarded Subjects.  ISNR Meeting Sweden 2004.​

  • The Effects of Neurofeedback Treatment in Down’s Syndrome.  ESNR Conference, Italy 2003.​

  • The Effects of Neurofeedback Treatment in Down’s Syndrome.  APB Conference, USA 2003.

INTERNATIONAL WORKSHOPS AND SYMPOSIUMS

  • QEEG and EEG Feedback in Psychiatry: Clinical Applications. Symposium, APA Yearly Meeting, San Diego, CA, 2012.​

  • QEEG Guided Neurofeedback Training Seminar.  BFE Annual Meeting Eindhoven, NL 2009.​

  • Psychopharmacology and EEG; QEEG Guided Neurofeedback Training, SAN and COST B27 Electric Neuronal Oscillations and Cognition 2nd Yearly Conference Seville, 2008.​

  • QEEG Guided Neurofeedback Training.  APA Yearly Meeting, San Diego, CA, 2007​

  • QEEG Workshop in the Neurofeedback Social Education Center. Starnberg, Munich 2004.

PHARMACOLOGY AND F-MRI RESEARCH EXPERIENCE

1997-1998 I worked under the supervision of Dr. Wexler at Yale during my residency in psychiatry. I was the primary responsible physician after Dr. Wexler to carry the research and data analysis.  Emotion (Happiness and Sadness) centers localization assessed in Humans with f-MRI.

 

1994-1995 I worked under Dr. Ronald Fieve at the NYSPI and the Foundation for Depression and   Manic Depression. I have been involved in carrying out FDA drug studies.

​

1994 Nefazadone against Prozac & Zoloft in Major Depression, compare the side effects and efficacy, Phase III study.

​

1994 Adatanserine vs Placebo in Anxiety Disorders, Phase II study.

​

1995 Organon 4428 vs Placebo&Prozac in Major Depression, Phase II study.

​

1995 Bristol Myers 1810 vs Placebo in Major Depression, Phase II study.

​

1992-1993 I worked under the supervision of Dr. Hemysfield at the St. Luke’s Hospital. I was charge of  the IGF-1 vs placebo clinical double blind study. Study was terminated due to extreme side effects.

​

1989-1992 I worked at NYI clinical research center, affiliate of NY Med. College and NYU. I was involved carrying out the clinical Psychopharmacology FDA Drug trial studies under the supervision of Drs. Turan Itil, Baron Shopsin and Hikmet Irkılata during my fellowship training.

​

1992 Gingko Biloba vs. Placebo in Major depression, Phase II study.

​

1991 Gingko Biloba vs. Placebo in Alzheimer’s D., Phase II study, Multi center 5 years study.

​

1990 B. Myers 1XXX vs. Placebo in Major Depression, Phase II study.

​

1990 Organon 4XXX vs. Placebo in Major Depression, Phase II study.

​

1990 Nimodipine vs. Placebo in Multi Infarct Demantia, Phase II study.

​

1989 Nimodipine vs. Placebo in Alzheimer’s D., phase II study,7 years longitudinal study.

A LOOK AT EVIDENCE-BASED NEUROPSYCHIATRIC MEDICINE

The most important finding for physicians in Irving Krisch's meta-analysis and the STAR*D studies is that antidepressants used in real-world (clinical) patients are minimally effective. We need to reconsider the role of antidepressants in evidence-based treatment.


Years ago, I went to the USA to study biological psychiatry and psychopharmacology, and as someone who was accepted to residency in Psychiatry at prestigious Ivy League universities (Harvard, Yale, Columbia, Cornell, University of Pennsylvania, Dartmouth Medical School), Johns Hopkins, Washington University, Duke University, University of Chicago, Albert Einstein College of Medicine, and the Institute of Living/University of Connecticut, which conduct the most ambitious drug research in biological psychiatry, I was so convinced back then that drugs would be a solution that I thought they could only cure brain disorders.

 

Since returning from America in 2000, more than 26,000 adult, adolescent, and child patients have applied to our clinic because they could not be cured with multiple psychotropic medications (antidepressants, antipsychotics, and amphetamines). A cost analysis is necessary. Seeing that medications were ineffective in these patients, I began applying biofeedback, family therapy, hypnosis, and cognitive therapy methods.

Biofeedback is a very natural method that teaches us to control our subconscious mechanisms, and significant clinical improvement can be seen in even 10 days in many depression patients who do not respond to medication.

 

Even though this method is accepted by patients, it is quite sad to see that it does not receive as much attention as ineffective medications, that antidepressants are frequently used by psychiatrists and doctors from other branches, and that there are few controlled studies of biofeedback on large cases due to insufficient funding for research.


I believe in the use of personalized treatment methods. I am in favor of using medication if necessary, and if medication is ineffective, applying new methods with the patient's consent, whether from the same or a different group of medications. We have seen that over 5000 patients, who did not improve with other methods (mostly medication), benefited from and improved with our QEEG-based Neurobiofeedback method.

*
Kirsch I, Moore T, Scoboria A, Nichols S: The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002; 5:article 23.

Pigott, H.E., Leventhal, A.M., Alter, G.S., Boren, J.J. (2010). Efficacy and Effectiveness of Antidepressants: Current Status of Research. Psychother Psychosom. February 22;79:267–279.

bottom of page